Citius Pharmaceuticals Inc vs Clear Secure Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Clear Secure Inc trades at $47.14 (market cap $4.98B). The key difference: Clear Secure Inc is far larger — about 248.9× Citius Pharmaceuticals Inc's market cap, and Clear Secure Inc pays a 1.19% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | YOU | |
|---|---|---|
Market Cap | $20.01M | $4.98B |
Sector | Health | Technology |
52-Week High | $1.82 | $62.36 |
52-Week Low | $0.48 | $29.61 |
Enterprise Value | $16.23M | $4.13B |
Dividend Yield | — | 1.19% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Clear Secure (YOU) trades at $47.31, down 7.63% over 24 hours, reflecting a bearish technical trend with support near $45. Fundamentally, the company reported strong Q2 2026 earnings of $0.49 per share, beating estimates, with revenue growth to $1.0 billion projected for 2026 and a net income margin of 14.78%. Recent news highlights expansion of its CLEAR1 platform and corporate membership launches, driving investor optimism despite recent price pressure.
The outlook is mixed: robust earnings beats and strategic initiatives support growth, but high valuation ratios (P/E of 32.62) and bearish technical signals pose risks. Analysts are divided with a 44% buy rating, suggesting cautious optimism amid volatility. Key risks include execution challenges and competitive pressures in identity verification services.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →